MIRA announces positive preclinical PTSD data for Ketamir-2 in rat model

MIRA PHARMACEUTICALS, INC.

Ketamir-2 reversed stress-induced avoidance, anxiety, and despair in rats after 5 daily oral doses.
Results from Single Prolonged Stress model showed behavior normalized to non-stressed animal levels.
Ketamir-2 is also in a Phase 1 trial for neuropathic pain with a favorable safety profile to date.
DEA concluded Ketamir-2 is not a controlled substance under the Controlled Substances Act.
A larger follow-on PTSD study in animals is ongoing; results support further development.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.